top of page
JAZMINE
ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER
CLINICAL TRIAL DETAILS
TO DETERMINE THE RECOMMENDED PHASE II DOSE AND EVALUATE THE PRELIMINARY ANTITUMOR ACTIVITY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
12
120
Phase Ib/II
Spain
SET UP
PRESS RELEASE
-
SCIENTIFIC IMPACT
-
BLOG ARTICLES RELATED
-
TRIAL SITES
-
bottom of page